TY - JOUR
T1 - Somatostatin analogues
T2 - Treatment of pituitary and neuroendocrine tumors
AU - Colao, Annamaria
AU - Faggiano, Antongiulio
AU - Pivonello, Rosario
PY - 2010
Y1 - 2010
N2 - This chapter summarizes the most recent data on the use of the somatostatin analogues (SSAs), octreotide (OCT) and lanreotide for the treatment of patients with pituitary and neuroendocrine tumors (NETs). These two analogues have a high affinity for somatostatin receptor (SSR) sub-types 2 and 5. The major indications of these compounds are GH-and TSH-secreting pituitary adenomas, secreting NETs and non-functioning NETs in progression. Pasireotide is a new analogue, with a receptor pattern different from previous analogues since it binds with high affinity to SSR types 1, 2, 3 and 5. This analogue will be available to treat patients with ACTH-secreting adenomas in a short time. A recent study has also demonstrated a beneficial effect of OCT long-acting release in patients with non-functioning NETs independently from their progression status. These data open the treatment with SSAs in all NET patients.
AB - This chapter summarizes the most recent data on the use of the somatostatin analogues (SSAs), octreotide (OCT) and lanreotide for the treatment of patients with pituitary and neuroendocrine tumors (NETs). These two analogues have a high affinity for somatostatin receptor (SSR) sub-types 2 and 5. The major indications of these compounds are GH-and TSH-secreting pituitary adenomas, secreting NETs and non-functioning NETs in progression. Pasireotide is a new analogue, with a receptor pattern different from previous analogues since it binds with high affinity to SSR types 1, 2, 3 and 5. This analogue will be available to treat patients with ACTH-secreting adenomas in a short time. A recent study has also demonstrated a beneficial effect of OCT long-acting release in patients with non-functioning NETs independently from their progression status. These data open the treatment with SSAs in all NET patients.
KW - Neuroendocrine tumors (NET)
KW - Octreotride
KW - Pituitary tumors
KW - Somatostatin
KW - Somatostatin analogues
UR - http://www.scopus.com/inward/record.url?scp=77956639140&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77956639140&partnerID=8YFLogxK
U2 - 10.1016/S0079-6123(10)82012-6
DO - 10.1016/S0079-6123(10)82012-6
M3 - Article
C2 - 20541670
AN - SCOPUS:77956639140
SN - 0079-6123
VL - 182
SP - 281
EP - 294
JO - Progress in Brain Research
JF - Progress in Brain Research
IS - C
ER -